Brief: Neuren Pharmaceuticals Informed Of Negative Trend Vote On MAA For Trofinetide
03/02/2026 24:44
Feb 3 (Reuters) - Neuren Pharmaceuticals NEU.AX: WAS INFORMED OF A NEGATIVE TREND VOTE ON ITS MAA FOR TROFINETIDE ACADIA TO REQUEST RE-EXAMINATION OF CHMP OPINION ACADIA WAS INFORMED BY COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE OF EUROPEAN MEDICINES AGENCY Further company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union